Topic Listing for BIONOVO INC

Administration Adoption Fas 123r
Amendment Bionovo Inc Stock Incentive Plan Amendment Stock Incentive Plan
Annual Incentive Bonus Program Approval Amendment Equity Incentive Plan
Assets Held Capital Leases Assignment Form
Audit Committee Authority
Base Salary Basic Diluted Loss Per Share
Basis Consolidation Basis Presentation
Because Limited Manufacturing Experience Depend Third-party Manufacturers Manufacture Benchmarking Cash Equity Compensation
Beneficial Owner Shares Registered Name Broker Bank Beneficial Ownership Reporting Compliance
Beneficial Ownership Securities Benefits Perquisites
Bionovo Announces 2008 Financial Results Bionovo Announces Closing Public Offering Common Stock
Bionovo Inc Bionovo Inc Development Stage
Bloomberg Business
Business Strategy Cash Equivalents Short-term Investments
Cashless Exercise Certain Transactions
Change Vote After Submitting Proxy Changes Capital Structure
Changes Internal Controls Chapter Title Usc 1350
Claims Relating Improper Handling Storage Disposal Biological Hazardous Clinical Trials Design
Code Ethics Commitments Contingencies
Common Stock Common Stock Delisted Nasdaq Capital Market Determined Penny
Compensation Discussion Analysis Compensation Nominations Committee
Compensation Nominations Committee Interlocks Insider Participation Competition
Competitors Develop Market Products Effective Existing Product Candidates Comprehensive Loss
Contacts Conversion Convertible Notes Common Stock
Corporate Governance Corporate Transactions Changes Control
Critical Accounting Policies Estimates Current Global Economic Environment Poses Severe Challenges Business
David Naveh Deferred Revenue
Delaware Delegation Subcommittee
Develop Existing Product Portfolio Development Stage
Dilutive Issuance Dilutive Issuance Notice
Diversify Application Drug Candidates Extended Indications Dividends
Documents Incorporated Reference Drug Development Programs Require Substantial Additional Future Funding
Duration Termination Amendment Election Directors
Eligibility Emeryville Calif
Employee Benefit Plan Employees
Employment Separation Agreements Entry Material Definitive Agreement
Equity Compensation Equity Grant Practices
Equity Incentive Plan Estimates
Evaluation Disclosure Controls Procedures Exact Name Registrant Specified Charter
Exchange Act Filings Executive Compensation Components
Executive Compensation Philosophy Objectives Executive Officers Directors
Exempt Issuance Exercise Date
Exercise Price Exhibits
Expect Rely Heavily Collaborative Relationships Termination Programs Reduce Explanatory
Face Uncertainty Commercialization Product Candidates Relating Coverage Pricing Failure Obtain Regulatory Approvals Foreign Jurisdictions Prevent Marketing
Failure Secure Patents Other Proprietary Rights Challenges Those Federal Income Tax Information
Financial Statement Schedules Financial Statements Exhibits
Find Out Results Voting Annual Meeting Focus Cancer Womens Health
Form 10-q Formation
Forward Looking Statements Foster Academic Industry Collaborations
General General Administrative Expenses
George Butler Phd Government Regulation Environmental Issues
Held 2008 History
History Net Losses Expect Continue Foreseeable Future Result History Net Losses Expect Continue Least Several Result
Holder Holders
Householding Proxy Materials Http Wwwbionovocom
Http Wwwbionovocom Homephpmenuinvestorssubmenucorporategovernance Income Tax
Income Taxes Independence Board Directors
Index Index Financial Statements
Information Information Regarding Committees Board Directors
Inherent Limitations Effectiveness Controls Initial Exercise Date
Intangible Assets Patent Costs Integrate Scientific Discoveries Natural Substances Used Traditional Chinese
Intellectual Property Patent Protection Interest Income Expense Other
Isaac Cohen John Baxter
Leases Leases Commitments Contingencies
Letter Credit Limitation Audit Committees Role
Limitation Liability Officers Directors Indemnification Limited Operating History Considered Development Stage
Liquidity Liquidity Capital Resources
Lose Services Co-founders Serve Directors Officers Operations Disrupted Louis Drapeau
Managements Annual Report Internal Control Over Financial Reporting Manufacturing
Marketing Sales Mary Tagliaferri
Maximum Percentage Measurement
Meetings Meetings Board Directors
Membership Merger Bionovo Inc Biopharmaceuticals
Merger Cost Michael Vanderhoof
Need Additional Capital Conduct Operations Develop Products Ability New Plan Benefits
Nominees Non-employee Director Compensation
Not Anticipate Paying Cash Dividends Foreseeable Future Therefore Notes Condensed Financial Statements
Notes Payable Notice Exercise
Off-balance Sheet Financings Liabilities Operations Might Interrupted Occurrence Natural Disaster Other Catastrophic
Options Exercised Other Collaborations
Other Events Other Matters
Outstanding Equity Awards Overview
Part Part Financial Information
Part Other Information Parties Successfully Assert Infringed Patents Proprietary Rights Challenge
Payable Person
Personam Pharmacology
Potential Payments Termination Change Control Potential Products Face Significant Regulatory Hurdles Prior Marketing
Pre-approval Policies Procedures Principal Accountant Fees Services
Principal Stockholders Significant Voting Power Take Actions Not Pro Forma Information Period Prior Adoption Fas 123r
Product Candidates Difficulties Market Acceptance Even After Fda Product Development Commercialization Involves Number Uncertainties Never Generate
Products Them Approved Subject Restrictions Withdrawal Market Penalties Property Equipment
Proposal Provided
Provisions Charter Documents Delaware Law Discourage Takeover Stockholders Purpose
Receiving Materials Recent Accounting Pronouncements
Registered Public Offering Regulation Disclosure
Related-person Transactions Policy Procedures Report Audit Committee Board Directors
Report Compensation Nominations Committee Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Internal Control Research Development
Research Development Activities Research Development Expenses
Restrictive Legend Event Results Operations
Results Operations Financial Condition Revenue Recognition
Revenues Sales Marketing Expenses
Sales Stock Executive Officers Directors Adversely Affect Price Sarbanes-oxley Act 2002
Scientific Advisory Board Scientific Consultants
Scientific Discovery Platform Anticancer Drugs Scientific Discovery Platform Hormone Replacement Therapy Selective Estrogen
Screening Philosophy Sec
Securities Authorized Issuance Equity Compensation Securities Exchange Act 1934
Securities Removed Nasdaq Listing Difficulty Purchasing Selling Common Security Ownership Certain Beneficial Owners Management
See Accompanying Notes Condensed Consolidated Financial Statements Share-based Compensation
Shares Reserved Future Issuance Signature
Signatures Simplified Employee Pension Plan
Stock Option Plan Stock Subject Incentive Plan
Stock Warrants Stock-based Compensation
Stockholder Communications Board Directors Stockholder Proposals Due Next Annual Meeting
Stockholder Record Shares Registered Name Stockholder Return Comparison
Subsequent Events Substantial Risk Product Liability Claims Business Unable Obtain
Table Contents Tax Considerations
Termination Date Terms Options
Terms Other Equity Awards Terms Stock Bonus Awards
Terms Stock Unit Awards Thomas Chesterman
Trading Trading Market
Unable Protect Trade Secrets Interests Proprietary Know-how Not United Biotech Corporation
United States Securities Exchange Washington 20549 Valuation Assumptions
Volatility Stock Price Adversely Affect Stockholders Vote
Vote Annual Meeting Votes
Votes Counted Votes Needed Approve Each Proposal
Warrant Share Delivery Date Washington 20549
What Broker Non-votes What Mean Receive Proxy Card
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Voting 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki